Empowering mobility

and independence.

ABLE is a powered orthosis for spinal cord injured individuals that allows them to stand up from the wheelchair and walk again.

ABLE is the first lightweight, easy-to-use and affordable exoskeleton for people with lower-limb paralysis, that restores the ability to walk naturally and intuitively.

It helps in palliating health issues caused by sedentary lifestyle while boosting self-confidence and independence.

Lightweight

Easy-to-use

Affordable

In only 2 years we went from an idea to a functional prototype successfully tested in subjects with spinal cord injury.

2018

· Company Incorporation

· Market Validation 100 interviews with MDs, PTs, and patients

· Proof of Concept Prototype

· Partnership with Institut Guttmann, UPC and Ingenia

2019

· Investor’s ready Business Plan

· Regulatory Strategy Report

· International Advisory Board

· Peer Review Publication

· Patent WO2018073252A1 in National Phases

· Seed Investment Round

· Usability Study with 15 SCI subjects

2020

· Government Grants

· Team Growth: 12 people

· Collaborations with leading rehabilitation institutions

· Prototype ready for Clinical Investigation

· Filed a second Patent

· Multicenter Clinical Investigation (for SCI, hospital use)

· Quality System Implementation

2021

· ISO 13485 Certification

· Manufacturer’s License (AEMPS)

· Exoskeleton Design Freeze

· Comparative Crossover Clinical Trial (vs standard of care)

· Medical Articles published

· Stroke exoskeleton Pilot Study

· Bridge Investment Round

2022

· ABLE Exoskeleton CE Mark as Class IIa MD

· Multicenter Clinical Investigation (for SCI, home use)

· Clinical Efficacy Trials

· Stroke exoskeleton Clinical Investigation

· Series A Investment Round

2023

· First Sales to Clinical Institutions in ES, GER, Nordics, Benelux

· Clinical Trial in United States

· ABLE Exoskeleton CE Certification for Homecare use

· Agreements with Distributors

2024

· Sales to Clinical Institutions in FRA, ITA, UK, IL

· FDA Clearance

· CE Mark Stroke exoskeleton

· First Sales to End-users